Samsung Bioepis said its European sales totalled $389 million for the first nine months of the year, The Korea Herald reported Wednesday.
The company noted that the sales of its products, namely Benepali and Flixabi, rose from $379.8 million in the year-ago period.
Regarding the quarter ended September 30, revenue from Benepali rose 24 percent year-over-year to $123.4 million, while sales of Flixabi jumped about four-fold to $11.4 million.
